Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-06-18

FDA Approved: NEUPOGEN — Supplemental Application (Amgen, Inc)

View source ↗

Summary

FDA approved a supplemental application for NEUPOGEN (filgrastim) from Amgen, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Neupogen (Filgrastim)

Snippet

SUPPL AP for NEUPOGEN (FILGRASTIM)